Venclexta (venetoclax) Tablet 100 Mg
Buy Venclexta (venetoclax) Tablet 100 Mg
 
Venclexta (venetoclax) Tablet 100 Mg, sold under the brand names Venclexta and Venclyxto, is a medication used to treat adults with chronic lymphocytic leukemia, small lymphocytic lymphoma, or acute myeloid leukemia. The most common side effects are low levels of neutrophils, diarrhea, nausea, anemia, nose and throat infection. Venclexta (venetoclax) Tablet 100 Mg
 
What is Venclexta/Venclyxto (venetoclax) for?
Venclexta/Venclyxto (venetoclax) is a B-Cell lymphoma-2 (BCL-2) inhibitor (chemotherapy) indicated for the treatment of adults with: 
 
Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL)
Newly-diagnosed acute myeloid leukemia (AML) in combination with azacitidine, or decitabine, or low-dose cytarabine, who:
are 75 years of age or older, or
have other medical conditions that prevent the use of standard chemotherapy.
 
indicated as monotherapy for the treatment of people with chronic lymphocytic leukemia (CLL), with or without the 17p deletion, who have received at least one prior therapy. The presence of 17p deletion can be assessed using specifically designed diagnostic tools. 
 
Venclexta/Venclyxto (venetoclax) in combination with rituximab is indicated for the treatment of adult patients with CLL who have received at least one prior therapy. Venetoclax is marketed in the USA, Canada and Australia under the name Venclexta and in the European Union under the name Venclyxto.
 
It is available in tablet form each containing either 10mg, 50mg or 100mg venetoclax.
 
How does Venclexta/Venclyxto (venetoclax) work?
CLL is a slow-growing disease in which too many immature lymphocytes (white blood cells) accumulate in the blood and bone marrow.
 
About 10% of patients with untreated CLL and approximately 20% of patients with relapsed CLL have a particular chromosomal abnormality (17p deletion)[6] that is related to a specific type of CLL named B-Cell lymphoma 2 (BCL-2).
 
Patients with CLL who have a 17p deletion lack a portion of the 17th chromosome the gene involved with the identification and elimination of faulty cells can be found. This gene thus acts to suppress cancer growth. In the presence of a 17p deletion, healthy cells are unable to use this identification/elimination pathway to prevent and control malignant cells.
 
Venetoclax is a selective inhibitor of a protein, named B-Cell lymphoma 2 (BCL-2 protein) that inhibits cell death (anti-apoptotic protein). Overexpression of the BCL-2 protein has been demonstrated in BCL-2 cells where it mediates tumour cell survival and has been associated with resistance to chemotherapeutics. Patients with the 17p deletion usually have poor outcomes with conventional chemo-immunotherapy. Venetoclax is the first approved treatment that helps restore the process of apoptosis (cell death) by binding directly to the BCL-2 protein and preventing the inhibition of cell death.
 
Where has Venclexta/Venclyxto (venetoclax) been approved?
Venclexta/Venclyxto (venetoclax) was approved by:
Food and Drug Administration (FDA), USA:
 April 11, 2016, for the treatment of patients with CLL or small lymphocytic lymphoma (SLL) with or without 17p deletion who have received at least one prior therapy.
October 16, 2020, for the treatment of newly diagnosed acute myeloid leukemia (AML) in combination with azacitidine, or decitabine, or low-dose cytarabine (LDAC)
 
European Medical Agency (EMA), European Union, December 5, 2016 for the treatment of CLL in the presence of 17p deletion or TP53 mutation in adult patients who are unsuitable for or have failed a B-cell receptor pathway inhibitor and for the treatment of CLL in the absence of 17p deletion or TP53 mutation in adult patients who have failed both chemoimmunotherapy and a B-cell receptor pathway inhibitor.
 
Therapeutic Goods Administration (TGA), Australia, January 5, 2017[9], in combination with rituximab, for the treatment of adult patients with CLL who have received at least one prior therapy. As monotherapy, it is indicated for the treatment of patients with relapsed or refractory CLL with 17p deletion or patients with relapsed or refractory CLL for whom there are no other suitable treatment options.
 
Health Canada:
September 2016, in combination with rituximab, for the treatment of patients with CLL who have received at least one prior therapy. As monotherapy it is indicated for the treatment of patients with CLL with 17p deletion who have received at least one prior therapy, or patients with CLL without the 17p deletion who have received at least one prior therapy and for whom there are no other available treatment options.
December 15, 2020, for newly diagnosed AML patients who are ineligible for intensive chemotherapy
 
MedSafe, New Zealand, November 2, 2017, in combination with rituximab, for the treatment of patients with CLL who have received at least one prior therapy. As monotherapy it is indicated for the treatment of patients with CLL with relapsed or refractory CLL with 17p deletion, or with relapsed or refractory CLL for whom there are no other suitable treatment options.
The Pharmaceuticals and Medical Devices Agency (PMDA), Japan on March 23, 2021.
 
Please note that this medicine may have also been approved in other regions than the ones we’ve listed. If you have a question about its approval in a specific country feel free to contact our support team for assistance.
 
Please be aware that any decision to use a prescription generic or brand name medicine should always be taken in consultation with a medical professional. The FDA has sent warning letters to drugmakers in India concerning the quality of their medicines.